

Supplement Table 1. Clinical characteristics of the patients used to construct the nomogram

Variables	Training set				Testing set			
	All (n=396)	Survival (n=264)	In-hospital mortality (n=132)	<i>P</i>	All (n=459)	Survival (n=368)	In-hospital mortality (n=91)	<i>P</i>
Age (years) (mean ±SD)	63.3±12.7	60.3±12.9	69.3±9.8	<0.001	62.1±12.8	59.8±12.4	70.2±11.3	<0.001
Male (n (%))	284 (71.7)	202 (76.5)	82 (62.1)	0.004	352 (76.7)	294 (79.9)	58 (63.7)	0.001
BMI (kg/m ²)	25.8 (24.6, 26.1)	26.0 (25.3, 26.5)	24.9 (24.4, 25.5)	<0.001	25.4 (23.4, 27.3)	25.5±3.0	25.3 (23.4, 27.5)	0.047
Cardiac arrest (n (%))	10 (2.5)	6 (2.3)	4 (3.0)	0.91	8 (1.7)	6 (1.6)	2 (2.2)	0.711
Cardiogenic shock before admission (n (%))	34 (8.6)	6 (2.3)	28 (21.2)	<0.001	30 (6.5)	15 (4.1)	15 (16.5)	<0.001
Use of temporary pacemaker before admission (n (%))	3 (0.7)	0	3 (2.3)	0.065	4 (0.9)	2 (0.5)	2 (2.2)	0.128
Ventilator support before admission (n (%))	6 (1.5)	1 (0.4)	5 (3.8)	0.029	7 (1.5)	2 (0.5)	5 (5.5)	0.001
CPR before admission	12 (3.0)	5 (1.9)	7 (5.3)	0.12	5 (1.1)	0	5 (5.5)	<0.001

	(n (%))							
SBP on admission								
(median (IQR))	128 (110, 146)	133 (114, 149)	118 (100, 140)	<0.001	125 (110, 140)	129±25	121 (107, 135)	0.009
DBP on admission								
(median (IQR))	79 (69, 89)	82 (72, 92)	73 (62, 82)	<0.001	77±16	80±15	69±16	<0.001
Heart rate on admission								
(median (IQR))	77 (65, 90)	76 (64, 89)	80 (66, 96)	0.025	79±18	78±17	82±24	0.095
Fatal arrhythmia before admission (n (%))	21 (5.3)	15 (5.7)	6 (4.5)	0.812	20 (4.4)	12 (3.3)	8 (8.8)	0.021
Total ischemic time								
(min (median (IQR)))	217 (124, 367)	154 (95, 250)	360 (194, 420)	<0.001	211 (130, 341)	194 (125, 307)	300 (222, 480)	<0.001
Killip class 3-4 (n (%))	132 (33.3)	95 (36.0)	37 (28.0)	0.142	119 (25.9)	66 (17.9)	53 (58.2)	<0.001
Past medical history								
<i>Hypertension (n (%))</i>	211 (53.3)	137 (51.9)	74 (56.1)	0.499	73 (15.9)	38 (10.3)	35 (38.5)	<0.001
<i>DM (n (%))</i>	96 (24.2)	49 (18.6)	47 (35.6)	<0.001	104 (22.7)	84 (22.8)	20 (22.0)	0.863

<i>Hyperlipidemia (n (%))</i>	39 (9.8)	12 (4.5)	27 (20.5)	<0.001	41 (8.9)	23 (6.3)	18 (19.8)	<0.001
<i>Previous PCI (n (%))</i>	18 (4.5)	8 (3.0)	10 (7.6)	0.073	23 (5.0)	17 (4.6)	6 (6.6)	0.44
<i>Previous CABG (n (%))</i>	1 (0.2)	0	1 (0.8)	0.157	1 (0.2)	0	1 (1.1)	0.05
<i>CAD (n (%))</i>	45 (11.4)	17 (6.4)	28 (21.2)	<0.001	40 (8.7)	20 (5.4)	20 (22.0)	<0.001
<i>AF (n (%))</i>	11 (2.8)	1 (0.4)	10 (7.6)	<0.001	13 (2.8)	3 (0.8)	10 (11.0)	<0.001
<i>HF (n (%))</i>	4 (1.0)	3 (1.1)	1 (0.8)	0.722	25 (5.4)	18 (4.9)	7 (7.7)	0.292
<i>Renal insufficiency (n (%))</i>	62 (15.7)	1 (0.4)	61 (46.2)	<0.001	13 (2.8)	1 (0.3)	12 (13.2)	<0.001
<i>History of cerebrovascular disease (n (%))</i>	64 (16.2)	40 (15.2)	24 (18.2)	0.53	72 (15.7)	60 (16.3)	12 (13.2)	0.464
<i>Peripheral vascular disease (n (%))</i>	9 (2.3)	5 (1.9)	4 (3.0)	0.721	5 (1.1)	3 (0.8)	2 (2.2)	0.255
<i>History of bleeding (n (%))</i>	2 (0.5)	1 (0.4)	1 (0.8)	>0.999	7 (1.5)	6 (1.6)	1 (1.1)	0.711
<i>Family history of CAD (n (%))</i>	44 (11.1)	28 (10.6)	16 (11.1)	0.875	68 (14.8)	62 (16.8)	6 (6.6)	0.014
<i>Angiographic characteristics</i>								
<i>Number of stents (median (IQR))</i>	1 (1, 1)	1 (1, 1)	1 (0, 1)	<0.001	1 (1, 1)	1 (1, 1)	1 (1, 1)	0.137

<i>Long lesions (n (%))</i>	245 (61.9)	178 (67.4)	67 (50.8)	0.002	194 (42.3)	131 (35.6)	63 (69.2)	<0.001
<i>Thrombus aspiration (n (%))</i>	123 (31.1)	92 (34.8)	31 (23.5)	0.029	221 (48.1)	205 (55.7)	16 (17.6)	<0.001
<i>Residual stenosis (n (%))</i>	12 (3.0)	2 (0.8)	10 (7.6)	0.001	10 (2.2)	4 (1.1)	6 (6.6)	0.001
<i>Use temporary pacemaker (n (%))</i>	22 (5.6)	4 (1.5)	18 (13.6)	<0.001	9 (2.0)	2 (0.5)	7 (7.7)	<0.001
<i>IABP (n (%))</i>	19 (4.8)	4 (1.5)	15 (11.4)	<0.001	15 (3.3)	4 (1.1)	11 (12.1)	<0.001
<i>Respirator support (n (%))</i>	20 (5.1)	1 (0.4)	19 (14.4)	<0.001	13 (2.8)	2 (0.5)	11 (12.1)	<0.001
<i>Pericardial aspiration (n (%))</i>	3 (0.8)	0	3 (2.3)	0.065	3 (0.7)	0	3 (3.3)	<0.001
<i>No flow (n (%))</i>	98 (24.7)	48 (18.2)	50 (37.9)	<0.001	84 (18.3)	55 (14.9)	29 (31.9)	<0.001
<i>Coronary perforation (n (%))</i>	5 (1.3)	0	5 (3.8)	0.001	2 (0.4)	1 (0.3)	1 (1.1)	0.283
<i>Dissection (n (%))</i>	3 (0.8)	0	3 (2.3)	0.065	5 (1.1)	0	5 (5.5)	<0.001
<i>Pericardial tamponade (n (%))</i>	9 (2.3)	0	9 (6.8)	<0.001	2 (0.4)	0	2 (2.2)	0.004
<i>Acute HF (n (%))</i>	55 (13.9)	22 (8.3)	33 (25.0)	<0.001	52 (11.3)	30 (7.7)	22 (24.2)	<0.001
<i>Bleeding (n (%))</i>	2 (0.5)	0	2 (1.5)	0.21	6 (1.3)	3 (0.8)	3 (3.3)	0.062
<i>Cardiac arrest (n (%))</i>	24 (6.1)	1 (0.4)	23 (17.4)	<0.001	14 (3.1)	6 (1.6)	8 (8.8)	<0.001
<i>Recurrent MI (n (%))</i>	16 (4.0)	1 (0.4)	15 (11.4)	<0.001	7 (1.5)	2 (0.5)	5 (5.5)	0.001

<i>Stent thrombosis (n (%))</i>	8 (2.0)	6 (2.3)	2 (1.5)	0.9	14 (3.1)	13 (3.5)	1 (1.1)	0.227
<i>Type B2-C (n (%))</i>	309 (78.0)	213 (80.7)	96 (72.7)	0.094	277 (60.3)	230 (62.5)	47 (51.6)	0.058
<i>TIMI flow grade 0-1 before PCI (n (%))</i>	311 (78.5)	197 (74.6)	114 (86.4)	0.011	339 (73.9)	274 (74.5)	65 (71.4)	0.556
<i>Use of GP IIb/IIIa inhibitors (n (%))</i>	92 (23.2)	54 (20.5)	38 (28.8)	0.064	107 (23.3)	80 (21.7)	27 (29.7)	0.109
<i>multivessel CAD (n (%))</i>	316 (79.8)	207 (78.4)	109 (82.6)	0.33	373 (81.3)	296 (80.4)	77 (84.6)	0.36
<i>LAD (n (%))</i>	149 (37.6)	85 (32.2)	64 (48.5)	0.002	209 (45.5)	177 (48.1)	32 (35.2)	0.027
<i>LCX (n (%))</i>	59 (14.9)	39 (14.8)	20 (15.2)	0.921	64 (13.9)	46 (12.5)	18 (19.8)	0.072
<i>RCA (n (%))</i>	101 (25.5)	101 (38.3)	40 (30.3)	0.119	144 (31.4)	120 (32.6)	24 (26.4)	0.251
Biochemical markers								
<i>Hyperkalemia (n (%))</i>	36 (9.1)	3 (1.1)	33 (25.0)	<0.001	30 (6.5)	11 (3.0)	19 (20.9)	<0.001
<i>Hyponatremia (n (%))</i>	29 (7.3)	12 (4.5)	19 (14.4)	0.001	37 (8.1)	31 (8.4)	6 (6.6)	0.566
<i>Anemia (n (%))</i>	26 (6.6)	12 (4.5)	14 (10.6)	0.022	40 (8.7)	21 (5.7)	19 (20.9)	<0.001
<i>Creatinine (median (IQR))</i>	86.2 (76.9, 90.6)	86.2 (70.6, 86.2)	90.6 (77.0, 95.5)	0.111	92.5 (64.5, 93.0)	85.1±32.1	91.1±53.5	0.17

<i>N/L ratio (median (IQR))</i>	5.47 (2.82, 10.00)	4.70 (2.68, 7.87)	8.54 (3.19, 11.46)	<0.001	6.15 (3.48, 9.52)	5.08 (3.65, 9.46)	9.1 (3.81, 12.51)	<0.001
<i>HCT, % (median (IQR))</i>	41.0 (37.1, 44.0)	41.8 (38.0, 44.6)	38.5 (36.8, 41.3)	<0.001	40.4 (37.4, 44.5)	40.0±5.2	38.0 (32.7, 43.3)	<0.001
<i>HGB, g/L (median (IQR))</i>	137.0 (126.0, 269.0)	142.0 (129.0, 155.0)	129.0 (119.0, 137.3)	<0.001	137.2±19.8	138.5±19.1	131.9±21.5	0.004
<i>PLT, ×10⁹/L (median (IQR))</i>	221.0 (183.5, 269.0)	224.0 (186.0, 269.0)	227.0 (194.8, 246.3)	0.554	225.0 (184.0, 260.0)	229.0 (187.0, 264.0)	215.0 (175.0, 254.0)	0.151
<i>Random blood glucose on admission, mmol/L (median (IQR))</i>	6.84 (5.47, 9.92)	5.95 (5.02, 7.44)	9.81 (7.96, 11.04)	<0.001	6.73 (5.27, 10.10)	6.12 (5.10, 8.10)	10.96 (8.40, 11.78)	<0.001
<i>EF after PCI (median (IQR))</i>	51.0 (43.0, 58.0)	54.0 (47.8, 59.0)	43.0 (38.0, 48.5)	<0.001	55 (46, 60)	56 (51, 61)	45 (37, 53)	<0.001
Medication list on admission								
<i>(n (%))</i>								
<i>Aspirin</i>	379 (95.7)	262 (99.2)	117 (88.6)	<0.001	404 (88.0)	332 (90.2)	72 (79.1)	0.004
<i>Ticagrelor/clopidogrel</i>	393 (99.2)	262 (99.2)	131 (99.2)	>0.999	418 (91.1)	332 (90.2)	86 (94.5)	0.199

<i>Ticagrelor</i>	223 (56.3)	162 (61.4)	61 (46.2)		218 (47.5)	183 (49.7)	35 (38.5)	
<i>clopidogrel</i>	170 (42.9)	100 (37.9)	70 (53.0)		200 (43.6)	149 (40.5)	51 (56.0)	
<i>ACEI/ARB</i>	133 (33.6)	100 (37.9)	33 (25.0)	0.014	25 (5.4)	18 (4.9)	7 (7.7)	0.292
<i>β-Blocker</i>	92 (23.2)	66 (25.0)	26 (19.7)	0.239	37 (8.1)	29 (7.9)	8 (8.9)	0.753
<i>Statin</i>	188 (47.5)	130 (49.2)	58 (43.9)	0.319	206 (44.9)	181 (49.2)	25 (27.5)	<0.001
mean duration of hospital stay (median (IQR))	8.51±5.11	9 (9,11)	1 (1,4)	<0.001	8.32±4.70	9 (8,11)	2 (1,5)	<0.001

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DM: diabetes mellitus; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CAD: coronary atherosclerotic heart disease; AF: atrial fibrillation; HF: heart failure; IABP: intra-aortic balloon pump; MI: myocardial infarction; LAD: left anterior descending branch; LCX: left circumflex artery; RCA: right coronary artery; N/L ratio: neutrophils/lymphocytes ratio; HCT: hematocrit; HGB: hemoglobin; PLT: platelets; EF: ejection fraction; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.